As we reported July 3, a Henry Ford Health System retrospective found a significant reduction in death for those treated with hydroxychloroquine over a non-treated group. Another recent study, not yet peer reviewed, is found on PrePrints. Published online July 3 and titled, “COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study,” the paper looks at 141 severe COVID-19 patients who received “the triple therapy”: zinc, low-dose HCQ, and azithromycin. Findings included that 2.8% of the treated group were hospitalized, compared with 15.4% for the control group. The Conclusion notes that “treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.”
CNN Cast Doubts: Political Hot Piece or Fair Critique?
In a July 2 article CNN say that while, “A surprising new study [Henry Ford] found the controversial antimalarial drug hydroxychloroquine helped patients better survive,” “the find...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).